来复枪
医学
急性肾损伤
肾脏替代疗法
入射(几何)
肾功能
人口
流行病学
肌酐
败血症
肾脏疾病
内科学
重症监护医学
物理
环境卫生
光学
考古
历史
作者
Tariq Ali,Izhar Khan,William G. Simpson,Gordon Prescott,Jonathan N. Townend,William C. Smith,Alison MacLeod
出处
期刊:Journal of The American Society of Nephrology
日期:2007-02-22
卷期号:18 (4): 1292-1298
被引量:803
标识
DOI:10.1681/asn.2006070756
摘要
Epidemiological studies of acute kidney injury (AKI) and acute-on-chronic renal failure (ACRF) are surprisingly sparse and confounded by differences in definition. Reported incidences vary, with few studies being population-based. Given this and our aging population, the incidence of AKI may be much higher than currently thought. We tested the hypothesis that the incidence is higher by including all patients with AKI (in a geographical population base of 523,390) regardless of whether they required renal replacement therapy irrespective of the hospital setting in which they were treated. We also tested the hypothesis that the Risk, Injury, Failure, Loss, and End-Stage Kidney (RIFLE) classification predicts outcomes. We identified all patients with serum creatinine concentrations ≥150 μmol/L (male) or ≥130μmol/L (female) over a 6-mo period in 2003. Clinical outcomes were obtained from each patient's case records. The incidences of AKI and ACRF were 1811 and 336 per million population, respectively. Median age was 76 yr for AKI and 80.5 yr for ACRF. Sepsis was a precipitating factor in 47% of patients. The RIFLE classification was useful for predicting full recovery of renal function (P < 0.001), renal replacement therapy requirement (P < 0.001), length of hospital stay [excluding those who died during admission (P < 0.001)], and in-hospital mortality (P = 0.035). RIFLE did not predict mortality at 90 d or 6 mo. Thus the incidence of AKI is much higher than previously thought, with implications for service planning and providing information to colleagues about methods to prevent deterioration of renal function. The RIFLE classification is useful for identifying patients at greatest risk of adverse short-term outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI